Inhibrx Biosciences Inc (Nasdaq:INBX), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, announced on Tuesday updated clinical data from the Phase 1/2 expansion study evaluating ozekibart (INBRX-109), an investigational tetravalent death receptor 5 (DR5) agonist, in combination with irinotecan and temozolomide (IRI/TMZ) in patients with relapsed or refractory Ewing sarcoma.
The data will be presented at the Connective Tissue Oncology Society (CTOS) 2026 Annual Meeting.
As of the data cutoff on 18 September, 60 patients (including 9 adolescent patients) were enrolled and treated with ozekibart plus IRI/TMZ, with 22 patients remaining on active treatment. Among the 51 response-evaluable patients, the combination demonstrated an overall response rate (ORR) of 62.7%, comprising 2 complete responses (CRs) and 30 partial responses (PRs). A total of 84.3% of response-evaluable patients (43/51) experienced measurable reduction in tumour size from baseline. An additional 12 patients achieved stable disease (SD), resulting in a Disease Control Rate (DCR) of 86.3%.
The median progression free survival (mPFS) was 6.0 months. Durable clinical benefit exceeding 6 months was observed in 18 patients (1 CR, 1 SD, 16 PRs), including 1 patient maintaining an ongoing PR for more than 2 years. At the cutoff date, 14 response-evaluable patients remained progression-free, including 2 patients with a PFS duration exceeding 12 months.
According to the company, these data represent a meaningful improvement over historical benchmarks, such as irinotecan and temozolomide alone in relapsed or refractory Ewing sarcoma, which typically yield an ORR of approximately 15% to 30% and mPFS of around 3 to 4 months.
Inhibrx said that the combination continued to demonstrate an acceptable and manageable safety profile consistent with the known cytotoxic toxicities of IRI/TMZ and DR5 agonism, with no evidence of unexpected cumulative hepatotoxicity.
The FDA has accepted for filing the biologics license application for the potential approval of ozekibart in conventional chondrosarcoma.
ViiV Healthcare receives positive EU recommendation for expanded paediatric HIV treatments
Rezolute's ersodetug meets primary endpoint in Phase 3 upLIFT study of tumour hyperinsulinism
Sunnyside adds GLP-1 options to its medication program for Alcohol Use Disorder
Traws Pharma reports final Phase 2a COVID-19 data and advances influenza programme
Shanton Pharma's SAP-001 receives EMA and FDA paediatric study waivers in hyperuricaemia
Ascletis announces submission of US IND application for oral obesity combination therapy
bioMérieux secures FDA clearance and IVDR CE marking for VITEK PRO diagnostic platform
Compass Pathways completes FDA application for COMP360 in treatment-resistant depression
bioMérieux secures FDA clearance for updated gastrointestinal diagnostic panels
Photocure maintains 2028 Medicare coverage target for AssureMDx following CMS update